Experience, Creativity And Dedication To Finding And Presenting The Best Investment Ideas
Contributor's Links: The Life Sciences Report

The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. 

The Streetwise Reports Team combines experience, creativity and ... more

ALL CONTRIBUTIONS

HIV Vaccine Clinical Study Results In High Immune Response Rates In Healthy Subjects
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. Inovio Pharmaceuticals Inc. has a "buy" rating.
Read
RXi Pharmaceuticals Receives Japanese Patent For RNAi Platform
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform.
Read
Regeneus Hits The Fast Track With Major Japanese Partnership
Regeneus, an Australian company, has entered into an collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Read
OncoSec Delivers Cancer Therapy Straight To The Tumor
OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor...
Read
With Potential Vaccines For Cancer, Ebola And Zika, Inovio Could Have An Explosive 2016
Recent news from Inovio Pharmaceuticals Inc., developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika could make the stock explode.
Read
Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain And Opioid Abuse
Relmada's Therapeutics Inc. Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
Read

STOCKS I FOLLOW

ABBV AbbVie Inc.
ABT Abbott Laboratories
ACAD ACADIA Pharmaceuticals Inc.
ACFN Acorn Energy Inc.
ACHN Achillion Pharmaceuticals Inc.
ACOR Acorda Therapeutics, Inc.
ACRX AcelRx Pharmaceuticals Inc.
ACTC ADVANCED CELL TECH
ADDXF ADDEX PHARMA ORD
ALPMF ASTELLAS PHARMA INC
AMBS Jumpkicks Inc
APRI Apricus Biosciences, Inc
ARIA ARIAD Pharmaceuticals Inc.
ARNA Arena Pharmaceuticals, Inc.
Load More

TWEETS

LATEST ACTIVITY

The Life Sciences Report
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR: https://t.co/9mZp827FqI more
The Life Sciences Report
Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray: https://t.co/IjA4tTQGTf $I...

more
The Life Sciences Report
. RXiPharma Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring: https://t.co/QLbMp5marh more
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications

The Life Sciences Report
Streetwise Reports

Focused on biotechnology, pharmaceuticals, medical devices, tools and diagnostics.